Cargando…
Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutation...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600068/ https://www.ncbi.nlm.nih.gov/pubmed/34804000 http://dx.doi.org/10.3389/fimmu.2021.686057 |
_version_ | 1784601069411631104 |
---|---|
author | Dong, Wen Lei, Pengfei Liu, Xin Li, Qin Cheng, Xiangyang |
author_facet | Dong, Wen Lei, Pengfei Liu, Xin Li, Qin Cheng, Xiangyang |
author_sort | Dong, Wen |
collection | PubMed |
description | Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutations in ALK gene, other mechanisms might contribute to tumor resistance to ALK tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a case of PD-L1-overexpressing lung adenocarcinoma that harbors both EML4-ALK gene rearrangement and BRAF mutation. In particular, a second molecular analysis after resistance to first- and second-generation ALK-TKIs revealed a high PD-L1 expression and tumor mutation burden. Therefore, treatment with nivolumab monotherapy, an anti-PD-1 inhibitor, was started and the patient achieved complete remission. This case report suggested that PD-1 inhibitors might be an effective treatment option for patients with multiple gene-driven PD-L1-expressing NSCLC harboring ALK gene rearrangement. |
format | Online Article Text |
id | pubmed-8600068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86000682021-11-19 Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Dong, Wen Lei, Pengfei Liu, Xin Li, Qin Cheng, Xiangyang Front Immunol Immunology Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutations in ALK gene, other mechanisms might contribute to tumor resistance to ALK tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a case of PD-L1-overexpressing lung adenocarcinoma that harbors both EML4-ALK gene rearrangement and BRAF mutation. In particular, a second molecular analysis after resistance to first- and second-generation ALK-TKIs revealed a high PD-L1 expression and tumor mutation burden. Therefore, treatment with nivolumab monotherapy, an anti-PD-1 inhibitor, was started and the patient achieved complete remission. This case report suggested that PD-1 inhibitors might be an effective treatment option for patients with multiple gene-driven PD-L1-expressing NSCLC harboring ALK gene rearrangement. Frontiers Media S.A. 2021-11-04 /pmc/articles/PMC8600068/ /pubmed/34804000 http://dx.doi.org/10.3389/fimmu.2021.686057 Text en Copyright © 2021 Dong, Lei, Liu, Li and Cheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Dong, Wen Lei, Pengfei Liu, Xin Li, Qin Cheng, Xiangyang Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma |
title | Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma |
title_full | Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma |
title_fullStr | Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma |
title_full_unstemmed | Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma |
title_short | Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma |
title_sort | case report: complete response to nivolumab in a patient with programmed cell death 1 ligand 1-positive and multiple gene-driven anaplastic lymphoma kinase tyrosine kinase inhibitor-resistant lung adenocarcinoma |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600068/ https://www.ncbi.nlm.nih.gov/pubmed/34804000 http://dx.doi.org/10.3389/fimmu.2021.686057 |
work_keys_str_mv | AT dongwen casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma AT leipengfei casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma AT liuxin casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma AT liqin casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma AT chengxiangyang casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma |